Cell Therapeutics to Resume Trading on MTA and NASDAQ

Tuesday , February 17, 2009 20:30ET

KNOBIAS: RAiDAR Story

SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors


SOURCE Cell Therapeutics, Inc.

Contacts:

Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com

CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.
Investors, Ed Bell
206-272-4345
Lindsey Jesch
206-272-4347
fax
206-272-4434
invest@ctiseattle.com

Investors - Cell Therapeutics, Inc. - Investors
all of Cell Therapeutics, Inc.


Public Companies Associated with this story:
CTIC

Knobias Subject Codes Associated with this story:
Market Listings

Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

KNOBIAS: RAiDAR Story

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.